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Syndecan‑3 regulates MSC 
adhesion, ERK and AKT signalling 
in vitro and its deletion enhances 
MSC efficacy in a model 
of inflammatory arthritis in vivo
Fiona K. Jones1,5, Andrei Stefan2,5, Alasdair G. Kay3, Mairead Hyland2, Rebecca Morgan2, 
Nicholas R. Forsyth4, Addolorata Pisconti1 & Oksana Kehoe2*
Rheumatoid arthritis (RA) is a debilitating and painful inflammatory autoimmune disease 
characterised by the accumulation of leukocytes in the synovium, cartilage destruction and bone 
erosion. The immunomodulatory effects of bone marrow derived mesenchymal stem cells (MSCs) 
has been widely studied and the recent observations that syndecan‑3 (SDC3) is selectively pro‑
inflammatory in the joint led us to hypothesise that SDC3 might play an important role in MSC 
biology. MSCs isolated from bone marrow of wild type and  Sdc3−/− mice were used to assess 
immunophenotype, differentiation, adhesion and migration properties and cell signalling pathways. 
While both cell types show similar differentiation potential and forward scatter values, the cell 
complexity in wild type MSCs was significantly higher than in  Sdc3−/− cells and was accompanied 
by lower spread surface area. Moreover,  Sdc3−/− MSCs adhered more rapidly to collagen type I 
and showed a dramatic increase in AKT phosphorylation, accompanied by a decrease in ERK1/2 
phosphorylation compared with control cells. In a mouse model of antigen‑induced inflammatory 
arthritis, intraarticular injection of  Sdc3−/− MSCs yielded enhanced efficacy compared to injection of 
wild type MSCs. In conclusion, our data suggest that syndecan‑3 regulates MSC adhesion and efficacy 
in inflammatory arthritis, likely via induction of the AKT pathway.
Syndecans are transmembrane heparan sulphate proteoglycans (HSPG) that consist of a core protein with hep-
aran sulphate glycosaminoglycan chains covalently attached to the ectodomain. They form part of the glycocalyx, 
which comprises a network of membrane-bound proteoglycans and glycoproteins on the surface of many dif-
ferent cell  types1. There are four mammalian syndecans, designated syndecan-1 (SDC1), -2, -3, and -4, which 
have protein cores with characteristic structural  domains2. The variable ectodomain, which is exposed to the 
extracellular environment, contains two or more heparan sulphate chains and in some cases also chondroitin 
sulphate chains. Through their ectodomain syndecans interact with a variety of extracellular and membrane 
proteins thus modulation many signalling pathways and biological processes including adhesion, proliferation, 
differentiation and  inflammation3,4. The hydrophobic transmembrane domain is followed by a short intracellular 
domain containing two domains highly conserved across all syndecans and a small highly variable domain which 
is unique across all four syndecans. The syndecan intracellular domain binds to cytoskeletal proteins, scaffold 
proteins and intracellular kinases involved in signal transduction and gene expression regulation, thus transduc-
ing signals collected by the extra cellular domain to both the cytoplasm and the  nucleus5,6.
Syndecan-3 (SDC3) has the largest core protein of all four mammalian syndecans and can harbour both 
heparan sulphate and chondroitin sulphate  chains7. SDC3 is expressed in several cell types and is involved 
in the regulation of growth factor  signalling8,9, Notch and BMP  signalling10,11, adhesion and  migration12,13, 
 proliferation10,14 and  differentiation10,15.
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Inflammation is a central feature of rheumatoid arthritis that affects around 1% of the population and can 
result in disability and morbidity. Chemokines are involved in stimulating the infiltration of leukocytes into 
inflamed tissue and the expression of a CXCL8 binding site on endothelial SDC3 in human RA suggests a role for 
this HSPG in inflammatory  disease16. We demonstrated that SDC3 plays a dual role in inflammation depending 
on the tissue and vascular bed. In the joint it is pro-inflammatory, since its deletion leads to reduced leukocyte 
recruitment and the severity of arthritis. However, in the skin and cremaster SDC3 plays an anti-inflammatory 
role, since its deletion leads to enhanced leukocyte interaction with the endothelium and  recruitment17. Fur-
thermore, an article recently published by Eustace et al. characterises the role of soluble SDC3 in inflammation 
using in vitro and in vivo  models18. The authors show that soluble SDC3 binds chemokines, reduces leukocyte 
migration in vitro and ameliorates disease severity in mouse models of arthritis. The observed anti-inflammatory 
mechanisms of shed SDC3 appear to be associated with competitive binding of SDC3 to chemokines, which limit 
their availability to recruit inflammatory  cells18.
Mesenchymal stem cells (MSCs) play a major role in the maintenance and regeneration of adult tissues 
subjected to physiological turnover or following  injury19. MSCs exert immunomodulatory functions, including 
inhibition of T cell proliferation, interference with B cell function and dendritic cell maturation and promo-
tion of anti-inflammatory macrophage-mediated  responses20–22. We previously demonstrated that MSCs reduce 
inflammation, joint swelling and cartilage destruction in a murine model of antigen-induced arthritis (AIA)17 
and hypothesise that SDC3 might play an important role in MSCs biology. A variant of SDC3 is expressed on 
the surface of human bone marrow stromal cells where it may be responsible for creating a stromal ‘niche’ for 
the maintenance and development of hemopoietic and progenitor  cells23. Here, we show a role for SDC3 dele-
tion on various murine MSC phenotypes, both in vitro and in vivo. MSCs isolated from syndecan-3 null mice 
show enhanced adhesion to collagen type I and hyperactivation of the AKT pathway, which are associated with 
increased efficacy of MSC treatment in a mouse model of AIA. Thus, our data further support the idea that 
pharmacologic targeting of SDC3 might constitute a potentially valuable therapeutic strategy for inflammatory 
arthritis.
Results
Characterisation of murine bone marrow MSCs. Wild type and SDC3 murine MSCs were successfully 
differentiated towards adipogenic, osteogenic and chondrogenic lineages after 21 days in culture with the relevant 
differentiation media. The differentiation potential was similar for both wild type and Sdc3−/− mMSCs (Fig. 1a). 
A colony-forming units assay was used to assess the proliferative capacity of the cells being expanded in culture, 
and the results showed both genotypes retained high proliferation rate in culture (Fig. 1b). The mean popula-
tion doubling time (PDT) value for Sdc3−/− MSCs was lower than that for wild type cells but was not statistically 
significant (Fig. 1c). Immunophenotypic analysis indicated similar surface marker expression pattern for both 
wild type and Sdc3−/− MSCs. Both sets of cells were negative for haematopoietic markers CD11b and CD45 and 
for the endothelial cell markers CD31, and positive for the mesenchymal markers CD44 and Sca-1. Expression 
of the general progenitor cell marker CD34 and of the vascular progenitor marker CD105 was highly variable in 
MSCs isolated from both genotypes, with a general trend of both markers being more commonly expressed in 
MSCs from Sdc3−/−mice compared with MSCs from wild type mice (Fig. 1d,e). Flow cytometry showed similar 
mean values for cell size (FSC, forward scatter) for both cell types (wild type: 112,146.53 ± 6324.64; Sdc3−/−: 
102,259.3533 ± 3460.25) (Fig. 1f). However, the spread cell surface area of adherent Sdc3−/− MSCs was consider-
ably lower when compared with wild type (Fig. 1g). Similarly, wild type MSCs showed significantly higher cel-
lular complexity, measured by side scatter (SSC) values then the Sdc3−/− MSCs (Fig. 1h).
Syndecan‑3 loss improves adhesion on collagen without affecting MSC migration. Crosstalk 
between extracellular matrix (ECM) components and MSCs is essential for tissue formation and maintenance. 
Syndecan-3 participates directly in cell adhesion the ECM as a collagen receptor, and might act as an integrin 
co-receptor by analogy to its close homolog  SDC113,24–27. Thus, we tested wild type and Sdc3−/− MSC adhesion to 
various ECM substrates. Without ECM coating, approximately 65% of wild type and Sdc3−/− cells were attached 
to tissue culture treated plates within 1 h of incubation (Fig. 2a), however, when seeded onto collagen-coated 
tissue culture plates, Sdc3−/− MSCs adhered more quickly than wild type MSCs (p = 0.014) (Fig. 2b). Similarly, 
fibronectin improved Sdc3−/− MSC adhesion by ~ 19% compared with wild type MSCs, although this difference 
was not statistically significant (Fig. 2c). Interestingly, laminin coating appeared to yield the opposite effect of 
collagen and fibronectin coating, although the difference in adhesion to laminin between wild type and Sdc3−/− 
MSCs was not statistically significant (Fig. 2d).
We further analysed the effect of syndecan-3 deletion on cell migration by the scratch and transwell assays. 
When cells were cultured in serum-free medium (SFM) or complete expansion medium (CEM) with either 
full serum content (FBS and HS, fCEM) or reduced serum content (CEM with 1% FBS and 1% HS, rCEM) in 
a scratch assay, wild type MSCs migrated slightly faster than Sdc3−/− MSCs but differences were not significant 
(Fig. 2e). To further investigate a potential role for SDC3 in MSC migration, we tested cell migration towards 
specific chemoattractants using a transwell assay. In the absence of chemoattractants, Sdc3−/− MSCs showed a 
tendency to migrate less than wild type MSCs, and although serum addition to the lower chamber increased 
MSC migration in a dose-dependent manner, the difference in migration between wild type and Sdc3−/− MSCs 
remained constant and non-statistically significant (Fig. 2f). Pleiotrophin is a major soluble ligand for SDC3 and 
acts as a chemoattractant for osteoblasts and neural progenitors in a SDC3-dependent  manner12. When pleiotro-
phin was added to low serum concentrations in the lower chamber of transwells it failed to enhance MSC migra-
tion (Fig. 2f). All these data together suggest that the slight migration defect observed in Sdc3−/− MSCs is due to 
an intrinsic property of Sdc3−/− MSCs rather than to a role for SDC3 in sensing external chemoattracting cues.
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Syndecan‑3 regulates ERK and AKT signalling pathways in MSCs. The results shown so far suggest 
a role for SDC3 in the regulation of MSC adhesion via one or more collagen receptors. Typical collagen receptors 
are integrins, which signal via several kinase-regulated pathways, and some tyrosine kinase  receptors28,29. Previ-
ous work demonstrated that Sdc3−/− satellite cell-derived myoblasts had a global increase in phosphorylated-
tyrosine (pY), suggesting SDC3 is involved in regulating numerous signalling pathways simultaneously. There-
fore, we first measured the levels of pY by western blot in wild type and Sdc3−/− MSCs but found no difference 
(Fig. 3a,b) and found no differences between the two genotypes.
Common kinase pathways downstream several adhesion complexes are the RAS/ERK pathways and the 
PI3K/AKT  pathway30. Thus, we investigated changes in phosphorylated AKT and ERK1/2. Here we found that 
Figure 1.  Characterisation of murine bone marrow MSCs. (a) Wild type and Sdc3−/− MSCs show a similar 
trilineage differentiation potential in vitro. Yellow scale bar represents 200 µm; black scale bar represents 
500 µm. The proliferative capability of MSCs were measured by (b) fibroblast colony-forming units and (c) 
average population doubling time (PDT). Dot plots displaying the percentage of cells expressing CD34 (d) 
or CD105 (e) as measured by flow cytometry. (f) The geometric mean of cell size was determined by forward 
scatter. (g) The morphometry, or cell spread, of cells were analysed using ImageJ. (h) The internal complexity 
of cells was measured by side scatter and the geometric means are shown. MSCs were isolated from wild type 
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the levels of  pAKTS473 were significantly increased in Sdc3−/− MSCs compared to wild type MSCs (Fig. 3c). In 
contrast, the levels of pERK1/2 significantly decreased when SDC3 was lost from MSCs (Fig. 3d), suggesting a 
role for SDC3 in inhibiting AKT signalling while promoting ERK1/2 signalling in MSCs adhering to collagen.
Syndecan‑3 loss in MSCs improves arthritic symptoms in AIA. The anti-inflammatory capability 
of MSCs from wild type and Sdc3−/− mice were tested in the AIA mouse model of inflammatory arthritis. This 
model shares many histopathological and clinical features seen in human  RA31. MSC treatments (wild type and 
Sdc3−/−) reduced joint swelling as a measure of joint inflammation compared to serum-free medium control at 
days 2 (p < 0.05) and 3 (p < 0.05) post arthritis induction (Fig. 4a). Significant reductions were also recorded in 
exudates in the joint cavity and cartilage loss at day 3 following MSC treatment and in overall arthritis index at 
day 3 post-arthritis induction (Fig. 4b). At day 7 post-arthritis induction, the histological scores were reduced 
but not significantly (Supplementary Figure 2). There were no significant differences in the histological param-
eters between knees treated with MSCs from wild type mice and knees treated with MSCs from Sdc3−/− mice.
Discussion
In this work we describe a role for the transmembrane proteoglycan SDC3 in MSC biology, with a particular 
focus on its role as an adhesion molecule and its involvement in MSC-mediated promotion of cartilage repair 
in a model of inflammatory arthritis.
Phenotypic characterisation of MSCs isolated from Sdc3−/− mice showed that the overall effect of SDC3 loss in 
mice does not produce dramatic effects on MSCs as Sdc3−/− retained multilineage potential in vitro and similar 
proliferation rates as wild type MSCs. Immunophenotyping analysis also revealed similar surface marker expres-
sion pattern for both wild type and Sdc3−/− MSCs. However, endoglin (CD105), a transmembrane glycoprotein 
that acts as an accessory to the transforming growth factor β (TGFβ) receptor  system32, was more commonly 
expressed in MSCs from Sdc3−/− mice compared with MSCs from wild type mice. Endoglin is an MSC marker 
and it is expressed in progenitor cells involved in vascular remodelling in animal models of myocardial infarction 
and rheumatic  diseases33,34. It has been shown that endoglin promotes angiogenesis in cell- and animal-based 
models of retinal neovascularisation and treatment with anti-CD105 antibody inhibits neovascularisation in 
oxygen-induced retinopathy  model35. Similarly, it has been shown that SDC3 inhibits angiogenic factor in vitro36 
Figure 2.  Adhesion to collagen is increased in Sdc3−/− MSCs. MSCs were isolated from wild type (n = 6) and 
Sdc3−/− (n = 6) mice and seeded onto several different substrates in complete expansion medium (CEM). After 
60 min the average percentage of wild type (WT) and Sdc3−/− MSCs adhered to each substrate was calculated: 
(a) Non-coated, (b) Collagen type I, (c) Fibronectin and (d) Laminin. (e) A scratch assay was performed on 
MSCs cultured in serum free medium (SFM), reduced serum content medium (rCEM) or full serum content 
medium (fCEM) and the average percentage of gap closure is shown. (f) Cell migration towards specific 
chemoattractants was measured using a transwell assay. The number of migrated cells was calculated after 
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Figure 3.  Loss of SCD3 in MSCs causes increased ATK phosphorylation and a reduction in ERK 
phosphorylation. MSCs were isolated from wild type (n = 6) and Sdc3−/− (n = 6) mice, cultured in full growth 
medium, and lysed ready for western blotting. (a) Representative images of blots used for quantification. SDC3 
knockout was confirmed for Sdc3−/− MSCs in each sample. (b) Total phosphorylated tyrosine normalised to 
GAPDH. (c) Phosphorylated  AKTSer473 was normalised to total AKT. (d) Phosphorylated  ERKThr202/Tyr204 was 
normalised to total ERK. Quantification was performed using ImageJ. Data displayed as mean ± standard 
deviation; *p < 0.05; **p < 0.01. Full-length blots are presented in Supplementary Figure 1.
Figure 4.  Effects of intra-articular injections of MSCs in AIA. (a) Knee diameter (mm) was used as an index of 
swelling (joint inflammation) and measured at days 1, 2, 3 and 7 post arthritis induction. Significant reductions 
are seen following Sdc3−/− MSCs and Sdc3+/+ MSCs injection in AIA mice. Data are means ± standard error of 
the mean (SEM) for right knee after subtraction of left knee control. *p < 0.05 comparing Sdc3−/− MSCs and 
control mice at the time points indicated; #p < 0.05 and ##p < 0.01 comparing Sdc3+/+ MSCs and control mice at 
the time points indicated. (b) The histological scoring for 3 days post arthritis induction. The arthritis index is 
the sum of all observations. Data are means ± SEM, n = 4 mice in each group; *p < 0.05 and ***p < 0.001.
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and that regenerating muscles of Sdc3−/− mice show enhanced  angiogenesis15. Thus, it is possible that the increase 
in CD105 expression in response to SDC3 loss might be linked to the SDC3-mediated regulation of angiogenesis 
that has been observed both in vitro and in vivo.
Obtaining a sufficient number of cells to initiate cell therapy is a limiting factor during therapeutic applica-
tions. Cells must be expanded in vitro prior to in vivo administration and cell adhesion is necessary for MSC 
expansion and further therapeutic  use37. Our results showed a role for SDC3 in the regulation of MSC adhesion 
via one or more collagen receptors. Previous work demonstrated the cooperation of α2β1 integrin with SDC1 
during adhesion to  collagen38, and cooperation of α2β1 integrin and α6β4 integrin with syndecans during adhe-
sion to  laminin39,40. A recent study has further confirmed that collagen promotes cell proliferation, cell survival 
under stress and a stronger cell adhesion to the cell culture  surface37. Since the attachment of MSC to collagen is 
mostly β1 integrin-mediated41, it is likely that SDC3 regulates MSC adhesion to collagen via β1 integrin.
Cell migration is an essential biological process involved many aspects of health and disease, including 
development, tissue regeneration, inflammation, and cancer progression. In this study we used two in vitro 
assays to study MSC migration, With the scratch assay, we studied the effects of cell–matrix and cell–cell inter-
actions on cell migration; with the transwell assay we studied the ability of cells to directionally respond to 
 chemoattractants42. Our results showed that wild type MSCs migrated slightly faster than Sdc3−/− MSCs in both 
assays, suggesting a role for SDC3 in the regulation of cell motility. Whether SDC3-mediated regulation of MSC 
migration is directly linked to SDC3-mediated regulation of adhesion or via other pathways, remains to be 
established. In other cell types SDC3 regulates migration by functioning as a ligand for the soluble factor heparin-
binding growth-associated molecule (HB-GAM) also known as  pleiotrophin43,44. However, pleiotrophin failed to 
enhance migration of both wild type and Sdc3−/− MSCs in our transwell assays, suggesting that, at least under our 
experimental conditions, SDC3-mediated regulation of MSC migration is not pleiotrophin-dependent. Moreover, 
since we observed the same slight difference in migration between wild type and Sdc3−/− MSCs regardless of the 
chemoattractant used, we conclude that such migration defect is due to an intrinsic property of Sdc3−/− MSCs 
rather than to a role for SDC3 in sensing external chemoattracting cues.
As discussed above, our data suggest that SDC3 regulates integrin-mediated MSC adhesion to collagen. 
Indeed, Sdc3−/− mMSCs cultured on collagen showed a dramatic increase in AKT phosphorylation, which was 
accompanied by a decrease in ERK1/2 phosphorylation compared with wild type controls. The adhesion and 
signalling phenotypes shown by Sdc3−/− MSCs are mirrored by the phenotypes reported for loss of α2 and α11 
integrin, both collagen I receptors, in human MSCs, which leads to decreased AKT phosphorylation, MSC 
adhesion to collagen I and cell  spreading45. Thus, our data strongly suggest a role for SDC3 in MSC adhesion 
and signalling by regulating integrin-collagen interaction.
The immunomodulatory effects of bone marrow derived mesenchymal stem cells (MSCs) has been widely 
studied and this current study has attempted to characterise the role that SDC3 plays in MSC biology. Deletion 
of SDC3 led to improvement of clinical scores, leukocyte recruitment and cartilage damage in a murine model of 
antigen-induced  arthritis17 suggesting that SDC3 contributes to the clinical manifestation of the disease. In the 
current work experiments, MSC treatments (wild type and Sdc3−/−) significantly reduced exudates in the joint 
cavity and cartilage loss at day 3 following MSC treatment and the overall arthritis index at day 3 post-arthritis 
induction. Sdc3−/− MSCs were more effective than wild type cells at reducing the overall disease severity. SDC3 
deletion enhances the efficacy of MSC treatment in an AIA model of inflammatory arthritis. Our study indicates 
important role for SDC3 in MSC biology which requires further investigation.
Materials and methods
Mice. Wild type mice, C57Bl/6 background, for MSC isolation and for the inflammatory arthritis model 
were obtained from Envigo, UK and housed in a pathogen-free facility at Liverpool John Moores University, in 
accordance with the Animals (Scientific Procedures) Act 1986 and the EU Directive 2010/63/EU, and after local 
ethical review and approval by the Animal Welfare and Ethical Review Body. Syndecan-3 null (Sdc3−/−) mice, 
sharing the same C57Bl/6 background as wild type mice (Reizes et al. 2001), were donated by Dr Rauvala, Uni-
versity of Helsinki and housed in a pathogen-free facility at the University of Liverpool, in accordance with the 
Animals (Scientific Procedures) Act 1986 and the EU Directive 2010/63/EU, and after local ethical review and 
approval by the Animal Welfare and Ethical Review Body.
Isolation, expansion, and characterisation of MSCs. MSCs were isolated from bone marrow of wild 
type (n = 6) and Sdc3−/− (n = 6) mice using a modified plastic adherence culture  method46. Isolated murine MSCs 
were cultured in complete expansion medium (CEM) (Iscove Modified Dulbecco Medium (IMDM) (Gibco, 
UK) supplemented with 9% foetal bovine serum (FBS) (Gibco, UK), 9% horse serum (HS) (Gibco, UK) and 1% 
penicillin–streptomycin (Lonza, UK)) and used between passage 3 and 5. Cells were characterised in terms of 
their surface markers through immunophenotyping, growth kinetics by population doubling time (PDT) assay 
and colony forming units fibroblast (CFU-F) assay, and trilineage differentiation potential (adipogenic, osteo-
genic and chondrogenic) as previously  described17. MSCs were tested for immunophenotype with the following 
antibodies: Ly-6A (Sca-1)-PE, CD44-PE, CD11b-PE, CD45-PE, CD105-PE, CD34-FITC and CD31-PE (all from 
eBioscience) using the FACSCanto II Flow Cytometer (BD Biosciences) and output data were assessed using 
Flowing Software 2.5.1 (Perttu Terho, Cell Imaging Core, Turku Centre for Biotechnology, University of Turku).
Adhesion assay. For cell adhesion assays, 96-well plates were coated with laminin, fibronectin or collagen 
type I at 1 µg/cm2 (Sigma-Aldrich, UK) overnight at 4 °C. After being blocked with BSA, 50 µl of 4 × 105 cells/ml 
were plated to each well. Plates were incubated for 60 min, and non-adherent cells were washed with PBS, fixed 
with 4% formaldehyde and labelled with 5 mg/ml crystal violet for 10 min. Unbound dye was washed away with 
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PBS, and the cells were lysed with 2% SDS before the absorbance at 550 nm was measured on FLUOstar OMEGA 
microplate reader (BMG Labtech, UK). Non-coated wells were also seeded and adhesion results were compared 
between the two cell genotypes. The percentage of cell attachment was determined relative to a set of standards 
with known cell numbers. Morphometric analysis was performed on 4% PFA-fixed, eosin (Sigma-Aldrich, UK)-
stained cells. Images were acquired at 4 × magnification using Olympus microscope IX-50 and quantitative data 
analysis was performed using ImageJ software (NIH, USA).
Migration: scratch assay and transwell assay. For cell migration/scratch assays, 24-well plates were 
coated with 1 µg/cm2 fibronectin overnight at 4  °C. 1 × 105 cells were seeded and incubated at  370C and 5% 
 CO2 until 80% confluence. The cell monolayer was scratched in a straight line using a p200 pipet tip. Cells were 
washed with PBS to remove the debris and smoothen the edges of the scratch and then the culture medium was 
replaced with either CEM with full serum content (9% FBS and 9% HS, referred to as fCEM), CEM with reduced 
serum content (1% FBS and 1% HS, referred to as rCEM) or serum free medium (contains all components of 
CEM but neither FBS or HS, referred to as SFM) to prevent cell proliferation during migration. A digital image of 
each scratch was acquired using Olympus microscope IX-50. Cells were then incubated for 24 h and all scratches 
digitally photographed again in the same location. For both time points ten vertical measurements of the cell 
layer gap were acquired, analysed using ImageJ software and the percentage of gap closure was calculated and 
compared between the two cell genotypes.
For transwell assays, 200 µl of 5 × 103 cells in rCEM were seeded on the upper side of transwell inserts for 
24-well plates (membrane 8.0 μm pores) (Sarstedt, UK). 500 µl of serum (FBS and HS (1:1)), rCEM or 10 ng/
ml of pleiotrophin in rCEM with 1% serum were added as chemoattractants in lower compartment. Serum free 
medium was used as control. Cells were incubated at 37 °C and 5%  CO2 for 15 h, fixed with 4% paraformaldehyde 
for 15 min at RT and then washed with PBS. Cells were stained with DAPI for 10 min protected from light. Cells 
were counted from 15 random microscope fields for each sample using Olympus microscope IX-5. Quantitative 
data analysis was performed using ImageJ software and results presented as number of migrated cells.
Western blotting. Cells were lysed in RIPA buffer (R0278, Sigma) supplemented with protease and phos-
phatase inhibitor cocktails (Roche), then homogenised by passing the lysate through 21G needle and syringe. 
Lysates were clarified by centrifugation and total protein content analysed by BCA assay. For analysis of SDC3 
protein levels, 100  μg of total protein was precipitated with methanol overnight at − 20  °C then centrifuged 
at 13,000 × g to pellet. Pellets were washed once with ice-cold acetone and resuspended in heparinase buffer 
(100 mM sodium acetate, 0.1 mM calcium acetate). Glycosaminoglycan chains were removed using 0.5 mU 
heparinase III (Ibex, Canada) and 0.5 mU chondroitinase ABC (Sigma) for 4 h at 37 °C. Total protein 20 µg (or 
40 µg for SDC3 analysis) was separated by SDS-PAGE and transferred onto nitrocellulose membranes (Hybond, 
GE Healthcare). Primary antibodies used were: p-AKT (1:3000, #4060, CST), AKT (1:3000, #9272, CST), p-ERK 
(1:3000, #9101, CST), ERK (1:3000, #9102, CST), p-Tyrosine (1:2000, #8954, CST), GAPDH (1:8000, G8795, 
Sigma) and SDC3 (0.14 µg/ml, AF2734, R&D). Secondary HRP-conjugated antibodies were used at 1:10,000 
(Santa Cruz). Membranes were visualised using chemiluminescence (Clarity ECL, Bio-Rad) and imaged using 
ImageQuant-Las4000 (GE Healthcare). Band intensity was analysed using ImageJ.
Antigen‑induced arthritis (AIA). Animal procedures were undertaken in accordance with Home Office 
project licence P0F90DE46. AIA was induced in 7- to 8-week-old male C57Bl/6 mice (7–8 weeks) as previously 
 described47. Briefly, mice were immunised subcutaneously with 1 mg/ml of methylated BSA (mBSA) emulsified 
with an equal volume of Freund’s complete adjuvant and injected intraperitoneally with 100 ml heat-inactivated 
Bordetella pertussis toxin, the subsequent immune response was boosted 1 week later. Then 3 weeks after the 
initial immunisation, AIA was induced by intra-articular injection of 10 mg/ml mBSA into the right knee joint 
and PBS into the left knee joint to serve as a control. Animals were inspected daily for arthritis development by 
measuring knee joint diameters using a digital micrometer (Kroeplin GmbH). The difference in joint diameter 
between the arthritic (right) and non-arthritic control (left) in each animal gave a quantitate measure of swelling 
(in mm).
Intra‑articular injection of MSC. After one day post arthritis induction, 10 µl of SFM, containing 5 × 105 
wild type or Sdc3−/− MSCs were injected intra-articularly (0.5 ml monoject (29 G) insulin syringe, BD Micro-
Fine, Franklyn Lakes, USA) through the patellar ligament into the right knee joint. Control animals were 
injected with SFM. Joint diameters were measured at 1, 2, 3, 5 and 7 days post injection. All measures were taken 
to reduce animal numbers (n = 4 per time point).
Arthritis index. Animals were sacrificed for histological analysis at days 3 and 7. Joints were fixed in 10% 
neutral buffered formal saline and processed as described  previously48. H&E sections were scored for hyperpla-
sia of the synovial intima (0 = normal to 3 = severe), cellular exudate (0 = normal to 3 = severe) and synovial infil-
trate (0 = normal to 5 = severe); and Toluidine Blue stained sections for cartilage loss (0 = normal to 3 = severe) 
by two independent observers blinded to experimental groups 47. Scores were summated, producing a mean 
arthritis index.
Statistical analysis. Statistical analysis was carried out on GraphPad Prism 5.0. A one-way ANOVA fol-
lowed by Tukey post hoc test was used for multiple comparisons and a two-tailed Student t test for comparisons 
of two variables. A p value < 0.05 was considered significant.
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